Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 26;37(10):2006–2016. doi: 10.1038/s41375-023-02010-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Three million Bos-1(CD19⁺TSLPR⁺) ALL PDX cells were I.V. injected into NSG mice, and Bos-1 engraftment were assessed by analyzing the percentage of ALL cells (hCD45⁺) in peripheral blood with flow cytometry. Humanization and treatment are same as in Fig. 3A. Leukemia burden was assessed as percentage of hCD45⁺/ TSLPR⁺ cells in single live cell population after humanization. A TSLPR antibody (1B4, BioLegend), non-competing with 1B7/CD3, was used for staining. A, B Tumor burden, in the blood, spleen, and bone marrow (BM) in (A) donor 076 (PBMC 076) and (B) 875 (PBMC 875) humanized mice treated with 0.1 or 1 mg/kg 1B7/CD3 or control (PBS). Spleen and BM were harvested 3 days post last dosing. Data are shown as mean ± SD; ***p < 0.001, **p < 0.01, *p < 0.05 compared with control. C Percentage of CD69 in CD3 T cells in the blood of donor 076 humanized mice (PBMC 076) treated with 0.1 or 1 mg/kg 1B7/CD3 or control (PBS) at week 2 post dosing. Data are shown as mean ± SD; **p < 0.01 compared with control. D Dynamic shifting of the T cell phenotype in the blood and spleen in donor 076 humanized mice (PBMC-076) treated with 1 mg/kg 1B7/CD3 or control (PBS). T_SCM, stem memory T cells; T_CM, memory T cells; T_EM, effector memory T cells; T_EMRA, effector memory cells re-expressing CD45RA T cells. E Percentage of CD3⁺ T cells in the blood, spleen, and BM in donor 076 humanized mice (PBMC-076) treated with 0.1 or 1 mg/kg 1B7/CD3 or control (PBS). Blood samples were collected at indicated times; spleen and BM samples were collected at 3 days post last dosing. Data are shown as mean ± SD; ***p < 0.001 compared with control. F Immunohistochemistry (IHC) analysis of CD3 T cells in the spleen and BM in donor 076 humanized mice treated with 0.1 or 1 mg/kg 1B7/CD3 or control (PBS) at 3 days post last dose. G HLA-A IHC analysis (upper panel) and hematoxylin & eosin staining in BM (lower panel) in donor 076 humanized mice at 3 days post last dose. Yellow circles indicate mouse polymorphonuclear cells; red arrows indicate mouse megakaryocytes.